TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• TG Therapeutics has received a consensus rating of "Moderate Buy" from five research firms, with an average twelve-month price target of $48.00.
• Insider Sagar Lonial sold 20,852 shares at an average price of $32.24, reflecting an 18.15% decrease in his stock ownership.
• In the most recent quarter, TG Therapeutics reported a net income margin of 13.31% but fell short of earnings expectations, with an EPS of $0.17 compared to the estimated $0.32.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $48.00.

Several equities research analysts have recently commented on TGTX shares. The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a research note on Thursday, July 10th. B. Riley lifted their target price on TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday.

TG Therapeutics Price Performance

TGTX stock traded down $0.24 during midday trading on Wednesday, reaching $32.37. 3,197,005 shares of the company's stock traded hands, compared to its average volume of 2,056,701. The company has a 50-day simple moving average of $31.91 and a two-hundred day simple moving average of $35.65. TG Therapeutics has a 1-year low of $21.16 and a 1-year high of $46.48. The company has a market cap of $5.14 billion, a price-to-earnings ratio of 87.49 and a beta of 1.88. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company's revenue for the quarter was up 92.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares of the company's stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently made changes to their positions in TGTX. Ameritas Advisory Services LLC acquired a new stake in shares of TG Therapeutics during the second quarter worth $25,000. Johnson Financial Group Inc. bought a new position in TG Therapeutics during the second quarter worth about $25,000. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics during the fourth quarter worth about $30,000. NBC Securities Inc. lifted its holdings in TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 823 shares in the last quarter. Finally, Golden State Wealth Management LLC lifted its holdings in TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 433 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.